Igf-1 Des
Peptide therapy: benefits, side effects, cost and protocols
IGF-1 DES is a truncated form of IGF-1 that lacks the first three amino acids of the N-terminus. This modification makes it approximately 10 times more potent than standard IGF-1 because it does not bind to IGF binding proteins, making more of it bioavailable for receptor activation.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Emerging Evidence
Mechanism
How Igf-1 Des works
Binds IGF-1 receptors with full affinity but has dramatically reduced binding to IGFBPs, resulting in higher free/active IGF-1 signaling at target tissues.
Evidence
Key studies
728 papers on PubMed / 447 human trials
- 01
Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis
- 02
Kaplan-Lefko PJ, Sutherland BW, Evangelou AI et al
Oncogene / Animal
- 03
Epithelial IGF-1 expression promotes prostate hyperplasia; negative selection required for metastasis
- 04
IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans
- 05
Hill DJ, Sedran RJ, Brenner SL et al
J Endocrinol / Animal
- 06
IGF-I exhibits dual effect on insulin release from isolated rat pancreatic islets
- 07
The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins
- 08
Guan J, Williams CE, Skinner SJ et al
Endocrinology / Animal
- 09
IGF-1 and IGF-2 reduce neuronal loss after hypoxic-ischemic brain injury in rats
- 10
The direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins
FAQ
Igf-1 Des questions
What is IGF-1 DES?
IGF-1 DES (Des(1-3) IGF-1) is a truncated form of IGF-1 lacking the first three amino acids, making it significantly more potent due to reduced binding protein affinity.
How does IGF-1 DES work?
Binds IGF-1 receptors with full affinity but has dramatically reduced binding to IGFBPs, resulting in higher free/active IGF-1 signaling at target tissues.
Is IGF-1 DES legal to buy?
IGF-1 DES is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy IGF-1 DES?
IGF-1 DES is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does IGF-1 DES belong to?
IGF-1 DES is primarily classified as a growth hormone secretion peptide. Peptides that stimulate or support growth hormone release, including GHRH analogs, GHRPs, and direct GH compounds for muscle, recovery, and anti-aging research.
What are the research benefits of IGF-1 DES?
IGF-1 DES has been studied for: Enhanced IGF-1 activity, Muscle hyperplasia, Localized tissue growth, Recovery support. Truncated IGF-1 variant; 10x more potent than intact IGF-1 due to reduced IGFBP binding.
News
Igf-1 Des in the news
New Insights into IGF-1 Signaling in the Heart - American Physiological Society Journal
American Physiological Society Journal / 8 months ago
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1 - Nature
Nature / 153 months ago
Study highlights characteristics of pediatric ambulatory central line associated bacterial infections - 2 Minute Medicine
2 Minute Medicine / 70 months ago
Efficient transdermal delivery of functional protein cargoes by a hydrophobic peptide MTD 1067 - Nature
Nature / 52 months ago
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy - Nature
Nature / 25 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Igf-1 Des?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.